Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T15:47:04.576Z.
Calculation as of: 2026-10-06T15:47:04.576Z.
Quote observation: 2026-10-06T15:45:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 88e906b5462319013e69f4ee379284aaffb96e00f9acc248208650345dd3e90c
PE RATIO
N/A
Market Cap
$6.55B
PE Ratio
42.08
TTM Avg
449.70
3Y Avg
488.80
5Y Avg
367.50
Market Cap
$6.02B
PE Ratio
32.14
TTM Avg
54.86
3Y Avg
51.97
5Y Avg
46.21
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunovant, Inc. (IMVT) | $6.74B | N/A | N/A | N/A | N/A |
| Chemed Corporation (CHE)vs › | $6.67B | 25.63 | 23.86 | 27.91 | 28.44 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.59B | N/A | 61.77 | 88.64 | 88.64 |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.55B | 42.08 | 449.70 | 488.80 | 367.50 |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 24.15 | 24.19 | 26.16 | 53.50 |
| Alkermes plc (ALKS)vs › | $7.09B | 110.42 | 44.92 | 25.77 | 27.28 |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.39B | N/A | 66.44 | 48.18 | 92.91 |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $6.02B | 32.14 | 54.86 | 51.97 | 46.21 |
| GRAIL Inc. (GRAL)vs › | $6.00B | N/A | N/A | N/A | N/A |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.95B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$32.64
Forward EPS (Est.)
$-2.94
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
